CytomX CTMX 深 滬
等待開盤 08-10 09:30:00 美东时间
3.46
+0.090
+2.67%
華盛通- 最 高3.55
- 今 開3.32
- 成交量 246.17万股
- 最 低 3.30
- 昨 收 3.37
- 總市值 7.53亿
- 52周最高 8.21
- 市盈率 靜 --
- 換手率 1.13%
- 52周最低 1.885
- 委 比 86.08%
- 總股本 2.18亿
- 歷史最高 35.00
- 量 比 0.90
- 振 幅 7.42%
- 歷史最低 0.40
- 每 手 1
- 風險率 1.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CytomX 2026年第二季度财报：合作收入下降推动亏损扩大
CytomX 2026年第二季度营收141.8万美元，同比下降约92.4%，稀释每股亏损0.09美元，净亏损扩大至2,066.6万美元；季度末现金及投资为3.303亿美元。
08-07 01:38
CytomX 2026年第二季度财报：营收降至141.8万美元，研发投入上升
CytomX 2026年第二季度营收141.8万美元，同比下降92.4%；稀释每股亏损0.09美元，净亏损2066.6万美元。期末现金及投资3.303亿美元，Varseta-M继续推进。
08-06 21:14
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
CytomX Therapeutics, Inc. has appointed Alejandra Carvajal as its new Chief Legal Officer. With over two decades of legal experience in the biotechnology sector, Carvajal will support the company's strategic and operational initiatives. She previously served as Chief Legal Officer at Mersana Therapeutics and Momenta Pharmaceuticals. CytomX, a clinical-stage oncology-focused biopharmaceutical company, is advancing its PROBODY® therapeutic platform...
08-03 12:00
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
CytomX Therapeutics announced it will report second quarter financial results on August 6, 2026, followed by a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT. Participants can access the webcast via the company’s website or register for the call in advance. The company, focused on developing conditionally activated biologics for cancer treatment, highlights its pipeline including varsetatug masetecan (Varseta-M) and CX-801. CytomX col...
07-30 12:00
Rigel appoints Alison L. Hannah as chief medical officer
Rigel Pharmaceuticals (RIGL) announced on Wednesday the appointment of Alison L. Hannah, M.D., to the role of executive vice president and chief medical officer. The company noted that Hannah has res...
07-01 20:58
CytomX Shareholders Approve Expanded Equity and Capital Plans
CytomX Therapeutics ( ($CTMX) ) just unveiled an update. CytomX Therapeutics’ s...
06-23 06:25
Alvotech seeks U.S. nod for biosimilars to J&J’s Simponi and Regeneron’s Eylea again
Alvotech (ALVO) shares spiked on Thursday after the company announced the resubmission of U.S. marketing applications for biosimilars AVT05 and AVT06 targeting Johnson & Johnson’s (JNJ) Simponi and Re...
06-05 02:34
Regeneron backed Parabilis seeks up to $476M in U.S. IPO
Parabilis Medicines (PBLS), a cancer drug developer backed by a recent research collaboration with Regeneron (REGN), has announced plans to raise up to $476M from its initial public offering in the U....
06-04 22:17
CytomX gains as licensing deal with Regeneron expands
CytomX Therapeutics (CTMX) traded higher in the morning hours on Wednesday after the cancer drug developer announced an expanded collaboration and licensing agreement with Regeneron Pharmaceuticals (R...
06-03 21:52
CytomX Expands Collaboration And Licensing Agreement With Regeneron To Create Conditionally-Activated Bispecific Cancer Therapies Utilizing CytomX's Probody Therapeutic Platform And Regeneron's Veloci-Bi Bispecific Antibody Development Platform
- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY® and Regeneron's Veloci-Bi® platforms -- CytomX to receive $37 million
06-03 20:04
